Eva-Lotta Allan
Direktor/Vorstandsmitglied bei ALMIRALL, S.A.
Ursprung des Netzwerks ersten Grades von Eva-Lotta Allan
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 26 | |
18
| Subsidiary | Biotechnology | 18 |
| Public Company | Biotechnology | 11 | |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
| Public Company | Pharmaceuticals: Major | 7 | |
Maxion Therapeutics Ltd.
 Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Draupnir Bio ApS
 Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Vertex Pharmaceuticals (Europe) Ltd.
 Vertex Pharmaceuticals (Europe) Ltd. Medical DistributorsDistribution Services Vertex Pharmaceuticals (Europe) Ltd. operates as a pharmaceutical firm. The company was founded on March 11, 1994 and is headquartered London, the United Kingdom.
2
| Subsidiary | Medical Distributors | 2 |
Aleta Biotherapeutics, Inc.
 Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Eva-Lotta Allan
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| University of Oxford | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| University of Barcelona | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| AVACTA GROUP PLC | Miscellaneous Commercial Services | Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | President President Director/Board Member Director/Board Member | |
| University of Antwerp | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Chairman Director/Board Member Chairman | |
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer Director/Board Member | |
| Ghent University | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member Director of Finance/CFO Director/Board Member | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Director/Board Member Director of Finance/CFO Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
| BIOTALYS NV | Chemicals: Agricultural | Director of Finance/CFO Director/Board Member | |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investment Managers | Director/Board Member Private Equity Investor | |
Sequana Medical AG
 Sequana Medical AG Medical SpecialtiesHealth Technology Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member Chairman | |
| GALAPAGOS NV | Biotechnology | Chairman Director/Board Member | |
Oxagen Ltd.
 Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Founder | |
Genomics England Ltd.
 Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| SYNAIRGEN PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Office for Strategic Co-ordination of Health Research | Chairman Director/Board Member | ||
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Chief Executive Officer Director/Board Member | |
| EYEPOINT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Bristol | College/University | Doctorate Degree Undergraduate Degree | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Graduate Degree | |
| University of Birmingham | College/University | Doctorate Degree Doctorate Degree | |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Chairman | |
Powderject Pharmaceuticals Plc
 Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Medical Specialties | Director/Board Member Founder | |
| Universitat Pompeu Fabra | College/University | Masters Business Admin Corporate Officer/Principal | |
| Université Libre de Bruxelles | College/University | Undergraduate Degree Doctorate Degree | |
Commerzbank Finance Ltd.
 Commerzbank Finance Ltd. Investment Banks/BrokersFinance Part of Commerzbank AG, Commerzbank Finance Ltd. is a British company that provides securities brokerage services. The company is based in London, UK. Commerzbank Finance was founded in 1955. | Investment Banks/Brokers | Director/Board Member Corporate Officer/Principal | |
| University of Glasgow | College/University | Doctorate Degree Undergraduate Degree | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Director of Finance/CFO Chief Tech/Sci/R&D Officer |
Statistik
International
| Vereinigtes Königreich | 28 |
| Belgien | 11 |
| Vereinigte Staaten | 5 |
| Spanien | 3 |
| Israel | 2 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 13 |
| Commercial Services | 5 |
| Process Industries | 3 |
| Finance | 3 |
Operativ
| Director/Board Member | 569 |
| Corporate Officer/Principal | 162 |
| Chairman | 117 |
| Independent Dir/Board Member | 80 |
| Chief Executive Officer | 71 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Enrique de Leyva Pérez | 44 |
| James Noble | 39 |
| Eliot Forster | 35 |
| Russell Greig | 31 |
| Roel Bulthuis | 29 |
| Rudy Dekeyser | 29 |
| Thomas Fulton Wilson McKillop | 28 |
| Samuel Cameron Williams | 27 |
| John Bell | 27 |
| Graziano Seghezzi | 26 |
| Denis Lucquin | 26 |
| Shah Hussain | 25 |
| John Berriman | 24 |
| Mats Gunnar Pettersson | 23 |
- Börse
- Insiders
- Eva-Lotta Allan
- Unternehmensverbindungen
